Denver Health And Hospital Authority

Denver Health And Hospital Authority, doing business as Denver Health, is a U.S. government entity and 555-bed academic healthcare system based in Denver, Colorado, that operates as both a prime federal contractor and prime grant recipient across health research, vaccine safety surveillance, and pharmaceutical safety monitoring programs. The organization competes in full-and-open procurements with no set-aside designations and derives its federal revenue from service contracts, indefinite-delivery agreements, and research grants rather than small-business set-asides.

Denver Health's federal footprint centers on post-marketing pharmaceutical surveillance, vaccine safety epidemiology, clinical research, and health services delivery to underserved populations. On the contract side, Denver Health holds a $149 million CDC multiple-award indefinite-delivery contract for the Vaccine Safety Datalink program (award date September 20, 2022, completion September 19, 2027), which supports ongoing vaccine safety monitoring and post-marketing drug surveillance under Executive Order 14398. In fiscal year 2024, this contract invoiced $1.3 million across 2.9 FTEs at a government-paid rate of $212.52 per hour, with work performed on a cost-no-fee basis at Denver Health's Denver facility. Denver Health also holds an $8.5 million FDA indefinite-delivery contract for non-medical use surveillance data reporting and analysis (award date September 30, 2026, completion September 29, 2031), compensated on fully burdened hourly labor rates across seven specified categories: Project Manager, Senior Computer Systems Analyst, Statistician, Pharmacist, Epidemiologist, Survey Scientist, and Subject Matter Expert. Recent task orders under FDA vehicles include a $330,746 delivery order for post-marketing prescription drug abuse surveillance data collection and analysis (September 30, 2026, completion September 29, 2027), a $309,340 order for the National Survey Investigating Hallucinogenic Trends (award date December 19, 2025, completion December 16, 2026), and a $1.208 million CDC Pittsburgh delivery order for evaluating the childhood vaccination schedule under the Vaccine Safety Datalink multiple-award IDIQ (award date August 23, 2026, completion June 30, 2028).

Customer concentration is dominated by the Department of Health and Human Services across its constituent agencies. The top customer by potential value is HHS Centers for Disease Control and Prevention Pittsburgh (19 awards, $218.9 million combined potential value), followed by FDA (22 awards, $35.4 million), CDC Office of Acquisition Services (10 awards, $27.8 million), HHS Agency for Healthcare Research and Quality (12 awards, $5.9 million), and NIH National Heart Lung and Blood Institute (19 awards, $2.1 million). These five agencies account for 99% of the combined potential value across Denver Health's award portfolio. Total award count across all federal sources spans 577 prime and sub awards (236 prime, 341 sub) with $293.1 million in combined potential value and $1.02 billion in combined obligated dollars. Activity has grown sharply — 16 awards in 2022 to 128 in 2024 — with 17 awards (combined potential value $8.1 million) reaching ultimate completion inside the next twenty-four months.

Denver Health's federal grant portfolio is substantial and research-intensive. Grant recipients include SAMHSA (Center for Substance Abuse Prevention, CFDA 93.492, $425,000 for the Engaging Youth Expertise for Prevention project through September 29, 2031; Center for Substance Abuse Treatment for the Judicial Substance Treatment & Recovery program through September 29, 2029), HHS Bureau of Health Professionals (CFDA 93.059, $113,460 for dental faculty loan repayment through August 31, 2031; CFDA 93.884, $346,474 for primary care training and street medicine curriculum through June 30, 2031; CFDA 93.226, $186,728 for emergency department linkage to care for homelessness through September 17, 2026), the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273, $189,000 for ketamine therapy in alcohol use disorder through August 31, 2031), the National Institute on Drug Abuse (CFDA 93.279, $634,042 for the National Survey Investigating Hallucinogenic Trends through December 31, 2030), the National Heart Lung and Blood Institute (stroke risk stratification in atrial fibrillation through March 31, 2030), and the National Science Foundation (CFDA 47.083, $100,000 planning grant for Lean Research Administration Model of Practice through July 31, 2025). Sub-grant activity shows Denver Health operates beneath state and university primes including the Colorado Department of Public Health & Environment, the Colorado Department of Health Care Policy & Financing, the University of Colorado, Emory University, Vanderbilt University Medical Center, and others, with sub-award work spanning HIV surveillance, tuberculosis control, WIC administration, maternal and child health, and emerging infectious disease programs.

On service contracts captured in the Service Contract Inventory, Denver Health reported $5.5 million in invoiced revenue across FY2022–FY2025 (primarily FY2022 and FY2024). SCI-reported invoicing reached $1.2 million in FY2022 across 7.9 FTEs and $4.3 million in FY2024 across 13.6 FTEs, with no FY2023 invoicing and minimal FY2025 activity recorded in the data snapshot. Government-paid rates on SCI prime records ran a median of $111.75 per hour, with senior labor pricing reaching $206.16 per hour and entry-level support around $32.84 per hour. Across SCI prime contracts, Denver Health self-performed all reported labor with no measurable subcontractor engagement. The organization's top SCI labor categories span special studies and analysis in medical and health contexts, support and administrative functions, housekeeping and guard services, and professional technical support.

Denver Health operates predominantly as a prime contractor on its federal work (41% prime, 59% sub across the full award portfolio) and builds its own delivery teams for research and epidemiological work; subcontractor relationships are minimal on SCI-reportable service contracts. As a sub-contractor, Denver Health provides clinical research and trial participation services to the University of Pittsburgh (CAVALIER Trial, a prehospital and in-hospital hemorrhagic shock study involving 11 Level I trauma centers, with a sub-award dated January 19, 2024). The organization's competitive posture is full-and-open across all major vehicles, with work routed through CDC, FDA, NIH, and HHS agency-wide IDIQs rather than small-business set-asides or HUBZone vehicles.